How does liraglutide compare to semaglutide?

Both are GLP-1 agonists, but liraglutide is the older, daily-injection version with about half the weight-loss effect (~8% vs ~15%). Semaglutide is once weekly and substantially more effective on weight. Liraglutide is still legitimate and well-studied — it has simply been outperformed.

What is the difference between Saxenda and Victoza?

Both are liraglutide. Saxenda is the higher-dose version approved for weight management; Victoza is approved for type 2 diabetes. Same molecule, different dose and indication.

Why would anyone use liraglutide over the newer drugs?

Mostly access, cost, tolerability, or clinician preference in specific situations. On raw efficacy the weekly agents win, but liraglutide has a long track record and hard cardiovascular-outcome data behind it. Any such choice is a medical decision, not something to self-direct.

Human RCTPrescription

Liraglutide

Also known as: Saxenda, Victoza

The first-generation daily GLP-1 agonist — well-studied and approved, but now clearly outclassed on weight loss by the weekly drugs that followed it.

Injectable

Last updated June 23, 2026

The drug that proved the GLP-1 weight-loss concept before semaglutide scaled it up. Approved as Saxenda (weight) and Victoza (diabetes), it has solid RCT data including a cardiovascular-outcome trial — but its mean weight loss (~8%) is roughly half what the newer weekly agents deliver, and it requires a daily injection. Useful mostly as the generational benchmark: it works, it is legitimate, and the field has moved past it.

Key finding: Mean ~8% body-weight reduction at 3.0 mg/day over 56 weeks (SCALE, Pi-Sunyer 2015)

Mechanism

Liraglutide is a GLP-1 receptor agonist, the same basic mechanism as semaglutide — it slows gastric emptying, acts on hypothalamic appetite centers to reduce intake, and enhances glucose-dependent insulin release. The difference is pharmacokinetic: a shorter half-life means once-daily rather than once-weekly injection. It was the GLP-1 that first carried this mechanism into approved weight management, which is why it matters historically even though the newer molecules hit the receptor (and, for tirzepatide, a second receptor) more effectively.

What the research shows

The data are real and predate the current wave. In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM), adults with obesity or overweight-with-comorbidity lost a mean of about 8% of body weight on liraglutide 3.0 mg daily over 56 weeks, versus roughly 2.6% on placebo — modest by today's standard but clearly significant at the time. On the diabetes side, LEADER (Marso et al., 2016, NEJM) was a large cardiovascular-outcome trial showing liraglutide reduced major adverse cardiovascular events versus placebo in type 2 diabetes with high cardiovascular risk. So liraglutide carries both weight-management and hard-outcome evidence. The honest framing: strong for its generation, but semaglutide and tirzepatide roughly double its weight effect with less frequent dosing, which is why it has lost ground.

Evidence grade: Human RCT — Randomized controlled trials in humans — the strongest evidence we grade.

Benefits studied

Mean ~8% body-weight reduction at 3.0 mg daily (SCALE, 56 weeks)
Reduction in major adverse cardiovascular events in high-risk type 2 diabetes (LEADER)
Improved glycemic control and progression-to-diabetes outcomes in prediabetes
Long real-world track record — one of the earliest approved GLP-1 agonists

Risks & unknowns

Boxed warning: GLP-1 agonists caused thyroid C-cell tumors in rodents; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
GI effects (nausea, vomiting, diarrhea) are common, particularly during titration
Reports of acute pancreatitis; discontinue if suspected
Gallbladder events can occur with the weight loss it produces
Requires a daily injection — adherence burden is higher than the weekly agents
Prescription drug; use belongs under a licensed clinician, not via grey-market sourcing

Regulatory status

Prescription. Available in the US only via prescription or a compounding pharmacy.

Goals studied: Fat loss, Body composition

FAQ

How does liraglutide compare to semaglutide?: Both are GLP-1 agonists, but liraglutide is the older, daily-injection version with about half the weight-loss effect (~8% vs ~15%). Semaglutide is once weekly and substantially more effective on weight. Liraglutide is still legitimate and well-studied — it has simply been outperformed.
What is the difference between Saxenda and Victoza?: Both are liraglutide. Saxenda is the higher-dose version approved for weight management; Victoza is approved for type 2 diabetes. Same molecule, different dose and indication.
Why would anyone use liraglutide over the newer drugs?: Mostly access, cost, tolerability, or clinician preference in specific situations. On raw efficacy the weekly agents win, but liraglutide has a long track record and hard cardiovascular-outcome data behind it. Any such choice is a medical decision, not something to self-direct.

Sources

[1]
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH · The New England Journal of Medicine · 2015 · PMID 26132939 · model: human
SCALE Obesity and Prediabetes RCT showing liraglutide 3.0 mg daily produced a mean ~8% body-weight reduction over 56 weeks versus placebo in adults without diabetes.
[2]
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB · The New England Journal of Medicine · 2016 · PMID 27295427 · model: human
LEADER outcome trial showing liraglutide reduced major adverse cardiovascular events versus placebo in adults with type 2 diabetes at high cardiovascular risk.